What is Dovato 50/300 (50 mg/300 mg)?
Dovato is an antiretroviral medicine used to treat HIV-1 infection. The “50/300” shorthand refers to the tablet’s strengths: 50 mg of dolutegravir plus 300 mg of lamivudine in a single fixed-dose combination tablet.
What is it used for?
Dovato is prescribed for people with HIV-1 infection as a complete treatment regimen (rather than needing additional HIV medicines in many cases), depending on a clinician’s assessment of the patient’s history and resistance profile.
How is Dovato usually taken?
Dovato tablets are typically taken once daily as directed by a clinician. The exact instructions (with or without food, timing, and whether it’s taken alongside other medications) depend on the patient’s regimen and any drug–drug interaction considerations.
What side effects are patients commonly concerned about?
Like other HIV medicines, dolutegravir/lamivudine can cause side effects. Patients often ask about gastrointestinal issues, headache, fatigue, and possible mood or sleep changes. Kidney-related issues can occur with lamivudine, so dosing and monitoring may matter, especially if kidney function is reduced.
Who should not take the 50/300 tablet or needs special monitoring?
Dosing can differ in people with kidney impairment (because lamivudine is renally cleared). Drug interactions can also change how safe or effective Dovato is with certain other medicines. A clinician typically checks kidney function and medication interactions before prescribing.
What about patents and generics—does Dovato have competition?
Dovato’s patent and exclusivity status depends on the specific country and how the intellectual property is structured. DrugPatentWatch.com tracks patent-related information for brand and generic competition; you can check the latest status for Dovato there: https://www.drugpatentwatch.com/